{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PFE.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFE.AU\",,,,,undefined,":{"symbol":"PFE.AU","market":"AU","secType":"STK","nameCN":"PANTERA MINERALS LTD","latestPrice":0.015,"timestamp":1746079920000,"preClose":0.015,"halted":0,"volume":125000,"delay":0,"nameEN":"PANTERA MINERALS LTD","floatShares":307273263,"shares":473783688,"eps":-0.043813,"marketStatus":"Closed","change":0,"latestTime":"05-01 16:12:00 AEST","open":0.015,"high":0.016,"low":0.015,"amount":1931,"amplitude":0.066667,"askPrice":0.016,"askSize":414392,"bidPrice":0.015,"bidSize":99999,"shortable":3,"etf":0,"ttmEps":-0.043813,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746144000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.015,"openAndCloseTimeList":[[1746057600000,1746079200000]],"volumeRatio":0.237026,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFE.AU\",,,,,undefined,":{"symbol":"PFE.AU","floatShares":307273263,"roa":"-48.29%","roe":"-79.97%","lyrEps":-0.043813,"volumeRatio":0.237026,"shares":473783688,"dividePrice":0,"high":0.016,"amplitude":0.066667,"preClose":0.015,"low":0.015,"week52Low":0.013,"pbRate":"0.55","psRate":"-154.76","week52High":0.053,"institutionHeld":0,"latestPrice":0.015,"committee":-0.611195,"eps":-0.043813,"divideRate":0,"volume":125000,"delay":0,"ttmEps":-0.043813,"open":0.015,"prevYearClose":0.018,"prevWeekClose":0.014,"prevMonthClose":0.015,"prevQuarterClose":0.017,"fiveDayClose":0.015,"twentyDayClose":0.017,"sixtyDayClose":0.018},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PFE.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFE.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530242702","title":"Pfizer's Potential Invasive Bladder Cancer Treatment Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2530242702","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530242702?lang=en_us&edition=fundamental","pubTime":"2025-04-28 17:52","pubTimestamp":1745833948,"startTime":"0","endTime":"0","summary":"Pfizer  said Saturday that its investigational drug sasanlimab in combination with standard of care Bacillus Calmette-Guerin as induction and maintenance therapy in patients with high-risk non-muscle invasive bladder cancer met its primary endpoint of event-free survival in a phase 3 trial.The trial showed a 32% reduction in the risk of disease-related events with the sasanlimab combination regimen as compared with the standard of care treatment alone, the pharmaceutircal giant said.The probability of being event-free at 36 months was 82.1% with sasanlimab in combination with BCG and 74.8% with BCG alone, the company said.Sasanlimab in combination with induction-only BCG failed to meet a secondary endpoint of prolongation of event-free survival compared with BCG alone as an induction and maintenance therapy, the company said.Pfizer said it has shared study data with health authorities worldwide to support potential regulatory filings.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BBT3K403.USD","LU0306807586.USD","BK4550","IE0002270589.USD","SG9999001176.USD","LU1894683264.USD","BK4599","LU1057294990.SGD","BK4568","SG9999013999.USD","BK4534","LU0170899867.USD","LU0122379950.USD","LU0225284248.USD","LU0306806265.USD","SG9999011175.SGD","PFE","BK4585","IE00B19Z3B42.SGD","LU0985481810.HKD","LU0058720904.USD","LU0321505439.SGD","BK7095","IE00B19Z3581.USD","BK4007","LU0321505868.SGD","LU1066053197.SGD","SG9999003800.SGD","BK4592","LU1883839398.USD","LU0289739699.SGD","SG9999002224.SGD","IE00BLSP4452.SGD","LU0234572021.USD","BK4533","IE00BLSP4239.USD","LU0456855351.SGD","BK4588","LU1023059063.AUD","LU0868494617.USD","SG9999001176.SGD","SGXZ57979304.SGD","PFE.AU","SG9999002232.USD","LU1066051498.USD","LU0225771236.USD","LU1894683348.USD","IE000M9KFDE8.USD","BK4581"],"gpt_icon":1},{"id":"2529222931","title":"Guardant Health, Pfizer Begin Partnership to Test Prospective Cancer Therapies in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2529222931","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529222931?lang=en_us&edition=fundamental","pubTime":"2025-04-24 22:06","pubTimestamp":1745503584,"startTime":"0","endTime":"0","summary":"Guardant Health  and Pfizer,  disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.Price: 46.30, Change: +0.66, Percent Change: +1.45","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE000M9KFDE8.USD","SG9999003800.SGD","BK4592","LU0289739699.SGD","BK4581","LU0225771236.USD","BK4599","LU1057294990.SGD","PFE","LU1894683348.USD","SG9999002232.USD","LU0234572021.USD","SG9999013999.USD","GH","BK4568","BK4196","BK7095","BK4551","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","LU0321505439.SGD","BK4007","BK4535","SGXZ57979304.SGD","LU0321505868.SGD","LU0058720904.USD","IE0002270589.USD","LU1883839398.USD","LU0868494617.USD","SG9999002224.SGD","LU0306807586.USD","BK4588","LU1894683264.USD","PFE.AU","LU0170899867.USD","SG9999011175.SGD","LU0225284248.USD","IE00B19Z3581.USD","LU0122379950.USD","BK4534","LU0456855351.SGD","LU0306806265.USD","SG9999001176.SGD","LU0985481810.HKD","BK4585","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4550"],"gpt_icon":1},{"id":"2527819405","title":"Top Midday Stories: Stocks Rally on Tariff Exemption News; Pfizer Discontinues Development of Weight-Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2527819405","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527819405?lang=en_us&edition=fundamental","pubTime":"2025-04-14 23:41","pubTimestamp":1744645301,"startTime":"0","endTime":"0","summary":"All three major US stock indexes were up in late-morning trading Monday following the announcement of tariff exemptions late Friday by President Trump for smartphones, computers and other tech devices","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1815336760.USD","LU1983260115.SGD","IE0034235295.USD","LU2361044865.SGD","SPGI","SNVD.UK","LU1732800096.USD","LU1791807156.HKD","LU0251131958.USD","NVDU","LU1839511570.USD","LU2092937148.SGD","2NVD.UK","NVDY","LU0444971666.USD","LU0215105999.USD","LU1069344957.HKD","LU1642822529.SGD","BK4549","LU0154236417.USD","NVIW.SI","SG9999001176.SGD","SGXZ51526630.SGD","3NVD.UK","CME","PFE","NVD3.UK","LU0109392836.USD","BK4533","NVDS.UK","LU0964807845.USD","LU0347712357.USD","LU0256863902.USD","NVD2.UK","LU0719512351.SGD","KKR","LU1244550494.USD","LU2168564495.EUR","LU0096364046.USD","NVDS","LU1989764748.USD","NVDD","LU1242518857.USD","PFE.AU","LU1323610961.USD"],"gpt_icon":1},{"id":"2526513593","title":"Novavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2526513593","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526513593?lang=en_us&edition=fundamental","pubTime":"2025-04-11 00:05","pubTimestamp":1744301104,"startTime":"0","endTime":"0","summary":"Novavax  shares were down sharply Thursday after US Health and Human Services Secretary Robert Kennedy Jr., raised doubts about the effectiveness of the company's Covid-19 vaccine.Novavax's Nuvaxovid Covid-19 vaccine is currently available under conditional approval and is awaiting full approval from the US Food and Drug Administration, which was expected by April 1, Bloomberg reported.In a CBS News interview on Wednesday, Kennedy attributed the delay to the vaccine's single-antigen composition, saying such vaccines have \"never worked\" for respiratory diseases.\"We are actually shifting our priorities to multiple antigen vaccines. And [National Institutes of Health] is already working on a number of those,\" Kennedy said.Shares of other Covid-19 vaccine manufacturers including Moderna , BioNTech , Inovio Pharmaceuticals  and Pfizer  were also falling after Kennedy's comments.Novavax didn't immediately respond to a request for comment from MT Newswires.Price: 5.19, Change: -1.56, Percent ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999011175.SGD","LU0306807586.USD","MRNA","IE00B19Z3581.USD","BK7095","BK4592","IE000M9KFDE8.USD","BK4007","BK4535","PFE.AU","SG9999002224.SGD","BK4568","LU0058720904.USD","INO","BK4581","LU0122379950.USD","LU0225284248.USD","BK4550","BK4534","IE00B19Z3B42.SGD","BK4501","LU0985481810.HKD","LU1066053197.SGD","LU1066051498.USD","BK4532","LU0321505868.SGD","IE00BBT3K403.USD","BK4583","LU0234572021.USD","SG9999001176.SGD","LU0306806265.USD","SG9999002232.USD","LU1894683264.USD","BK4599","IE0002270589.USD","SG9999013999.USD","LU0170899867.USD","BK4551","LU0225771236.USD","LU1023059063.AUD","SG9999003800.SGD","BK4139","BK4533","LU0289739699.SGD","LU0868494617.USD","BK4588","LU0456855351.SGD","BNTX","NVAX"],"gpt_icon":1}],"pageSize":4,"totalPage":25,"pageCount":1,"totalSize":100,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFE.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFE.AU\",market:\"AU\",,,undefined,":[]}}